Luoxin Pharmaceutical (shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Medshine Discovery Inc.

Genfleet Therapeutics (shanghai) Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Genfleet Therapeutics Inc.

Luoxin Pharmaceutical Co., Ltd.

Jianyu Lu

Charles Z Ding

Lihong Hu

Shuhui Chen

Huijun He

Jian Li

Jiaqiang Dong

Tie-Lin Wang

Shenyi Shi

Guoping Hu

Weidong Li

Lifang Wu

Fei Sun

Xu Zeng

Wen Jiang

Bin Shi

Xiangyu Fu

Wenqian Yang

Shuwen Duan

Zhijuan Chen

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Estrogen receptor antagonist

Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor

Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof. (I)

3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors

Disclosed in the present invention are a crystal form and salt form of a TGF-&#x3b2;R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers. 

Crystal form and salt form of TGF-&#x3b2;RI inhibitor and preparation method therefor

Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer. 

Crystal form of estrogen receptor inhibitor and preparation method therefor

Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers. 

Indolo substituted piperidine compound as estrogen receptor down-regulator

A benzotriazole-derived &#x3b1; and &#x3b2;-unsaturated amide compound used as TGF-&#x3b2;R1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I). 

Benzotriazole-derived &#x3b1; and &#x3b2;-unsaturated amide compound used as TGF-&#x3b2; RI inhibitor

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer. 

Substituted-indole-compounds as estrogen receptor down-regulators

Growing community of inventors

Shanghai, China

Jianyu Lu